Enanta Pharmaceuticals (ENTA) Lowered to “Neutral” at JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from an overweight rating to a neutral rating in a report published on Thursday morning, Marketbeat reports.

Several other analysts also recently commented on the company. Zacks Investment Research downgraded Enanta Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, January 30th. Royal Bank of Canada downgraded Enanta Pharmaceuticals from an outperform rating to a sector perform rating and set a $54.00 target price for the company. in a research note on Tuesday, January 2nd. Finally, TheStreet upgraded Enanta Pharmaceuticals from a c+ rating to a b- rating in a research note on Wednesday, December 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. Enanta Pharmaceuticals currently has an average rating of Hold and an average price target of $51.25.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded down $3.67 on Thursday, hitting $70.99. The stock had a trading volume of 273,394 shares, compared to its average volume of 222,031. The firm has a market cap of $1,705.63, a P/E ratio of 42.22 and a beta of 1.04. Enanta Pharmaceuticals has a 12 month low of $27.24 and a 12 month high of $95.91.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.13 by ($0.27). The firm had revenue of $75.93 million during the quarter, compared to analyst estimates of $73.80 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.82%. The business’s quarterly revenue was up 491.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.09) earnings per share. research analysts forecast that Enanta Pharmaceuticals will post -1.57 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Arizona State Retirement System grew its stake in shares of Enanta Pharmaceuticals by 224.3% in the 4th quarter. Arizona State Retirement System now owns 23,997 shares of the biotechnology company’s stock valued at $1,408,000 after buying an additional 16,597 shares during the period. Wells Fargo & Company MN lifted its position in Enanta Pharmaceuticals by 28.5% in the 4th quarter. Wells Fargo & Company MN now owns 23,388 shares of the biotechnology company’s stock valued at $1,373,000 after acquiring an additional 5,191 shares in the last quarter. LS Investment Advisors LLC lifted its position in Enanta Pharmaceuticals by 56.8% in the 4th quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock valued at $218,000 after acquiring an additional 1,345 shares in the last quarter. Teacher Retirement System of Texas bought a new position in Enanta Pharmaceuticals in the 4th quarter valued at about $286,000. Finally, Crossmark Global Holdings Inc. lifted its position in Enanta Pharmaceuticals by 34.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 8,300 shares of the biotechnology company’s stock valued at $487,000 after acquiring an additional 2,130 shares in the last quarter. Institutional investors own 67.86% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://sportsperspectives.com/2018/02/09/enanta-pharmaceuticals-enta-lowered-to-neutral-at-jpmorgan-chase-co.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply